{"url_path":"/sec/inmb/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-069611-index.html","accession_number":"0001213900-26-069611","cik":"0001711754","ticker":"INMB","issuer_name":"Inmune Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-069611-index.html","primary_entity_key":"0001711754","primary_entity_name":"Inmune Bio, Inc."},"word_count":84,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n10.1\n \n[Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan.](ea029512901ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n2\n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**INMUNE BIO INC.**\n\n \n \n\nDate: June 17, 2026\nBy:\n*/s/ David Moss*\n\n \n \nDavid Moss\n\n \n \nChief Financial Officer\n\n \n\n3"}